Biotech Values

[hptaxis]

Abiraterone Acetate For Prostate Cancer: A New Era Of Hormonal Therapies

Antonarakis ES. Abiraterone acetate for prostate cancer: a new era of hormonal therapies. Asian J Androl 2011 13: 663-664; advance online publication. http://www.nature.com/aja/journal/v13/n5/full/aja201192a.html / http://www.nature.com/aja/journal/v13/n5/pdf/aja201192a.pdf

In conclusion, the observation that treatment with abiraterone can prolong survival in men with castration-resistant prostate cancer provides a proof of principle that even this form of the disease remains androgen-driven, and paves the way for a new era of AR-targeted therapies for prostate cancer. As several novel androgen-modulating therapies (e.g., orteronel, MDV-3100, TOK-001 and ARN-509) enter clinical trials,13 the new challenge will be to determine how to optimally sequence or combine these agents with one another or with other established or experimental treatments for advanced prostate cancer. In addition, the role of abiraterone and other AR-directed therapies in men with earlier disease states is currently undefined. Hopefully, the next decade will shed some light on some of these questions.